<?xml version="1.0" encoding="UTF-8"?>
<STUDY_SET xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <STUDY alias="Relapse_and_Reinfection_in_Tuberculosis-sc-2011-11-29T12:38:29Z-2045" accession="ERP001037" center_name="The Wellcome Trust Sanger Institute">
    <IDENTIFIERS>
      <PRIMARY_ID>ERP001037</PRIMARY_ID>
      <EXTERNAL_ID namespace="BioProject">PRJEB2777</EXTERNAL_ID>
      <SUBMITTER_ID namespace="SC">Relapse_and_Reinfection_in_Tuberculosis-sc-2011-11-29T12:38:29Z-2045</SUBMITTER_ID>
      <SUBMITTER_ID namespace="The Wellcome Trust Sanger Institute">Relapse_and_Reinfection_in_Tuberculosis-sc-2011-11-29T12:38:29Z-2045</SUBMITTER_ID>
    </IDENTIFIERS>
    <DESCRIPTOR>
      <STUDY_TITLE>Relapse and Reinfection in Tuberculosis</STUDY_TITLE>
      <STUDY_TYPE existing_study_type="Whole Genome Sequencing"/>
      <STUDY_ABSTRACT>"Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study." Pubmed ID: 24461758. Whole-genome sequencing to establish relapse or re-infection with Mycobacterium tuberculosis: a retrospective observational study. Recurrence of tuberculosis after treatment makes management difficult and is a key factor for determining treatment efficacy. Two processes can cause recurrence: relapse of the primary infection or re-infection with an exogenous strain. Although re-infection can and does occur, its importance to tuberculosis epidemiology and its biological basis is still debated. We used whole-genome sequencing-which is more accurate than conventional typing used to date-to assess the frequency of recurrence and to gain insight into the biological basis of re-infection. We assessed patients from the REMoxTB trial-a randomised controlled trial of tuberculosis treatment that enrolled previously untreated participants with Mycobacterium tuberculosis infection from Malaysia, South Africa, and Thailand. We did whole-genome sequencing and mycobacterial interspersed repetitive unit-variable number of tandem repeat (MIRU-VNTR) typing of pairs of isolates taken by sputum sampling: one from before treatment and another from either the end of failed treatment at 17 weeks or later or from a recurrent infection. We compared the number and location of SNPs between isolates collected at baseline and recurrence. We assessed 47 pairs of isolates. Whole-genome sequencing identified 33 cases with little genetic distance (0-6 SNPs) between strains, deemed relapses, and three cases for which the genetic distance ranged from 1306 to 1419 SNPs, deemed re-infections. Six cases of relapse and six cases of mixed infection were classified differently by whole-genome sequencing and MIRU-VNTR. We detected five single positive isolates (positive culture followed by at least two negative cultures) without clinical evidence of disease. Whole-genome sequencing enables the differentiation of relapse and re-infection cases with greater resolution than do genotyping methods used at present, such as MIRU-VNTR, and provides insights into the biology of recurrence. The additional clarity provided by whole-genome sequencing might have a role in defining endpoints for clinical trials.</STUDY_ABSTRACT>
      <STUDY_DESCRIPTION>http://www.sanger.ac.uk/resources/downloads/bacteria/mycobacterium.html This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/</STUDY_DESCRIPTION>
    </DESCRIPTOR>
  </STUDY>
</STUDY_SET>
